20:38 , Mar 6, 2017 |  BC Extra  |  Clinical News

Researchers identify KEAP1 as AD target

In a manuscript published in PLoS Genetics, U.K. researchers identified Kelch-like ECH associated protein 1 (KEAP1) as a potential target to treat Alzheimer's disease. In a fly model, the scientists found that inhibition of KEAP1...
08:00 , Feb 18, 2016 |  BC Innovations  |  Product R&D

Crossing paths

Selina Koch, Staff Writer  With its first foray into the brain, Catabasis Pharmaceuticals Inc. is using its linker technology to simultaneously target the inflammatory and oxidative stress pathways that drive neurodegeneration, starting with amyotrophic lateral sclerosis...